Oral PI3K-δ,γ Inhibitor for the Management of People with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Narrative Review on Duvelisib

Overview of attention for article published in OncoTargets and therapy, March 2021

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 9 Dimensions

Readers on

mendeley: 15 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 9 publications that cite this research output.

9

The most recent citing publications are shown below. View all 9 publications that cite this research output on Dimensions.

Dual inhibition of phosphoinositide 3-kinases delta and gamma reduces chronic B cell activation and autoantibody production in a mouse model of lupus

Article in Frontiers in Immunology (May 2023)

PI3k Inhibitors in NHL and CLL: An Unfulfilled Promise

Article in Blood and Lymphatic Cancer Targets and Therapy (March 2023)

Duvelisib attenuates bleomycin‐induced pulmonary fibrosis via inhibiting the PI3K/Akt/mTOR signalling pathway

Article in Journal of Cellular and Molecular Medicine (January 2023)